H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
03 2019
Historique:
received: 24 03 2018
accepted: 14 08 2018
revised: 10 08 2018
pubmed: 7 10 2018
medline: 24 12 2019
entrez: 7 10 2018
Statut: ppublish

Résumé

Dedifferentiated chondrosarcoma is a rare bone sarcoma, whose genetic background remains incompletely understood. Mutations in SUZ12 or EED, which encode polycomb repressive complex 2 (PRC2) components, and resulting deficiency in H3K27me3 are characteristic features of the majority of malignant peripheral nerve sheath tumors. Here, we investigated H3K27me3 and PRC2 status in dedifferentiated chondrosarcoma. Among 19 evaluable dedifferentiated chondrosarcoma cases, six (32%) showed immunohistochemical loss of H3K27me3 only in the dedifferentiated component, whereas the well-differentiated component retained H3K27me3. H3K27me3-deficient dedifferentiated chondrosarcoma occurred in two men and four women with a median age of 66. All of these tumors affected bones of the upper half of the body, with the ribs being preferentially involved, which represented a significantly different distribution compared to that in the 13 H3K27me3-intact dedifferentiated chondrosarcomas. H3K27me3-deficient dedifferentiated chondrosarcomas were histologically different from H3K27me3-intact dedifferentiated chondrosarcomas, as the former invariably demonstrated dedifferentiated histology with a striking similarity to classic malignant peripheral nerve sheath tumor, comprising sweeping to swirling fascicles of relatively uniform spindle cells. Heterologous rhabdomyoblastic differentiation, the focal presence of grade 3 chondrosarcoma histology, and a cartilaginous component in the metastatic sites were exclusively seen in some cases of H3K27me3-deficient dedifferentiated chondrosarcoma. In all three H3K27me3-deficient dedifferentiated chondrosarcomas that contained focal grade 3 histology, dedifferentiated components did not juxtapose to the grade 3 areas but transitioned abruptly from the grade 1-2 components. Targeted next generation sequencing, which was successfully performed on four H3K27me3-deficient dedifferentiated chondrosarcomas, identified an IDH2 mutation in one case and COL2A1 truncations in three cases. The dedifferentiated areas of three cases harbored SUZ12 or EED alterations, which were absent in the well-differentiated component, suggesting a role for PRC2 aberrations in dedifferentiation. H3K27me3 deficiency defines a novel subset of dedifferentiated chondrosarcoma that requires recognition because of its diagnostic and potential clinical implications.

Identifiants

pubmed: 30291346
doi: 10.1038/s41379-018-0140-5
pii: S0893-3952(22)01096-1
doi:

Substances chimiques

Biomarkers, Tumor 0
Histones 0
histone H3 trimethyl Lys4 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

435-445

Auteurs

Naohiro Makise (N)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.
Department of Pathology, The University of Tokyo, Tokyo, Japan.

Masaya Sekimizu (M)

Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan.

Eiichi Konishi (E)

Department of Surgical Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Toru Motoi (T)

Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

Takashi Kubo (T)

Division of Translational Genomics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Tokyo, Japan.

Hisashi Ikoma (H)

Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Shun-Ichi Watanabe (SI)

Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.

Tomotake Okuma (T)

Department of Orthopaedic Surgery and Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

Nobuyoshi Hiraoka (N)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.

Masashi Fukayama (M)

Department of Pathology, The University of Tokyo, Tokyo, Japan.

Akira Kawai (A)

Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.
Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.

Hitoshi Ichikawa (H)

Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Division of Translational Genomics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Tokyo, Japan.

Akihiko Yoshida (A)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan. akyoshid@ncc.go.jp.
Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan. akyoshid@ncc.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH